ACADIA Pharmaceuticals Announces Proposed Public Offering of Common Stock

SAN DIEGO—(BUSINESS WIRE)—Mar. 3, 2014—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) today announced that itintends to offer and sell, subject to market and other conditions,$150,000,000 of shares of its common stock in an underwritten publicoffering. There can be no assurance as to whether or when the offeringmay be completed, or as to the actual size or terms of the offering.

Jefferies LLC and J.P. Morgan Securities LLC are acting as the jointbook-running managers for the offering. Cowen and Company, LLC is actingas the lead manager for the offering.

The shares of common stock described above are being offered by ACADIApursuant to a shelf registration statement filed by ACADIA with theSecurities and Exchange Commission (SEC) that became automaticallyeffective on March 3, 2014. A preliminary prospectus supplement relatedto the offering will be filed with the SEC and will be available on theSEC's website located at http://www.sec.gov.Copies of the preliminary prospectus supplement and the accompanyingprospectus relating to this offering, when available, may be obtainedfrom Jefferies LLC, Attention: Equity Syndicate Prospectus Department,520 Madison Avenue, 12th floor, New York, NY 10022 or by telephone at877-547-6340 or by email at Prospectus_Department@Jefferies.com,or from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions,1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at866-803-9204.

This press release shall not constitute an offer to sell or thesolicitation of an offer to buy these securities, nor shall there be anysale of these securities in any state or other jurisdiction in whichsuch offer, solicitation or sale would be unlawful prior to theregistration or qualification under the securities laws of any suchstate or other jurisdiction.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines that address unmet medicalneeds in neurological and related central nervous system disorders.ACADIA has a pipeline of product candidates led by pimavanserin, whichis in Phase III development as a treatment for Parkinson's diseasepsychosis. Pimavanserin is also in Phase II development for Alzheimer’sdisease psychosis and has successfully completed a Phase II trial as aco-therapy for schizophrenia. ACADIA also has clinical-stage programsfor chronic pain and glaucoma in collaboration with Allergan, Inc. andtwo advanced preclinical programs directed at Parkinson’s disease andother neurological disorders. All product candidates are small moleculesthat emanate from internal discoveries.

Forward-Looking Statements

Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the proposed offering of commonstock by ACADIA. These statements are only predictions based on currentinformation and expectations and involve a number of risks anduncertainties. Actual events or results may differ materially from thoseprojected in any of such statements due to various factors, includingmarket risks and uncertainties and the satisfaction of customary closingconditions for an offering of securities. For a discussion of these andother factors, please refer to ACADIA’s annual report on Form 10-K forthe year ended December 31, 2013 as well as ACADIA’s subsequent filingswith the Securities and Exchange Commission. You are cautioned not toplace undue reliance on these forward-looking statements, which speakonly as of the date hereof. This caution is made under the safe harborprovisions of the Private Securities Litigation Reform Act of 1995. Allforward-looking statements are qualified in their entirety by thiscautionary statement and ACADIA undertakes no obligation to revise orupdate this press release to reflect events or circumstances after thedate hereof, except as required by law.

Source: ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.
Thomas H. Aasen, ExecutiveVice President,
Chief Financial Officer and Chief BusinessOfficer
Lisa Barthelemy, Director of Investor Relations
(858)558-2871